News

Golar LNG Limited Secures $500 Million in Convertible Notes

Golar LNG Limited Secures $500 Million in Convertible Notes

Golar LNG Limited Secures $500 Million in Convertible Notes

Hamilton, Bermuda – Golar LNG Limited (NASDAQ: GLNG) has made a significant announcement regarding the pricing of its $500 million aggregate principal amount of 2.75% Convertible Senior Notes, which are due in 2030. This strategic financial maneuver is presented in a private placement aimed at qualified institutional buyers, as stipulated by Rule 144A under the Securities Act of 1933. To enhance this offering, the Company has also provided the initial purchasers with a 30-day option to acquire an additional $75 million in principal amount of these notes. The expected closing date for this offering is near the end of the month, pending the fulfillment of customary conditions.

Terms and Conversion Features of the Notes

The convertible notes represent senior, unsecured obligations of the Company. Carrying a fixed interest rate of 2.75% per annum, interest payments will occur semi-annually, starting December 15, 2025. Maturing on December 15, 2030, these notes can be converted at Golar’s discretion into common shares, cash, or a combination of both. The initial conversion rate is set at 17.3834 common shares per $1,000 principal, translating to an approximate conversion price of $57.53 per share, which is about 40% above the average market price observed prior to the announcement.

Redemption and Fundamental Change Clauses

These notes come with a flexible redemption policy. They can be redeemed in whole or in part by the Company starting December 20, 2028, provided that specific market conditions are met regarding the share price. This redemption is designed to align with favorable market conditions, ultimately benefiting shareholders while ensuring the Company’s financial positioning remains secure.

Use of Proceeds from the Offering

Proceeds from the sale of these convertible notes, including any exercised options, will primarily support the repurchase of 2.5 million shares of the Company's common stock. This strategic repurchase is part of a larger initiative to bolster shareholder value and fund various corporate goals. Beyond share repurchases, the funds will also facilitate future investments, including the planned development of a fourth floating liquefied natural gas (FLNG) unit, conversion costs for the MKII FLNG, and redeployment expenses associated with the Hilli vessel.

Investor Relations and Future Outlook

As Golar LNG Limited navigates this new financial chapter, it remains committed to transparency and communication with its stakeholders. Investors and interested parties can direct questions to the Company’s investor relations team, led by CEO Karl Fredrik Staubo, CFO Eduardo Maranhão, and Head of Investor Relations Stuart Buchanan. Contact information remains readily available for inquiries, reinforcing the Company’s dedication to investor engagement and satisfaction.

Frequently Asked Questions

What are the main features of Golar LNG's new convertible notes?

The convertible notes are worth $500 million with a 2.75% interest rate and are due in 2030. They can be converted into common shares or cash at Golar's discretion.

How will Golar LNG use the proceeds from the notes offering?

Proceeds will primarily fund the repurchase of shares and support various corporate investments, including future FLNG projects.

What is the initial conversion price for the notes?

The initial conversion price is set at approximately $57.53 per common share, reflecting a premium over recent market prices.

What happens if Golar LNG undergoes a fundamental change?

Holders of the notes can require the Company to purchase them for cash at a pre-defined price if a fundamental change occurs.

How can investors reach Golar LNG's investor relations?

Investors can contact Golar LNG's investor relations team via phone, with details provided in corporate announcements for inquiries related to investment matters.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 237

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 171

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 228

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 229

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 164

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 145

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 408

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 284

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 242

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 0

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading

Top 5 Most Recently Viewed Articles

Growth Insights in Account Based Marketing Platforms to 2030

Updated Category News Views 231

Account Based Marketing Platforms: The Path Ahead Middleton, Massachusetts – In a significant report by QKS Group, the global Account Based Marketing Platform (ABM) Market is charting a positive trajectory, with a projected compound annual growth rate (CAGR) of 12.01% extending through 2030. This analysis provides businesses with critical insights to adeptly navigate...

Continue Reading
XenDex Presale Countdown: Join the XRPL Revolution Today!

Updated Category News Views 157

Exciting Prospects for XenDex on the XRP Ledger The crypto landscape is buzzing with excitement as the XenDex project emerges as a noteworthy contender on the XRP Ledger. With only six days left in its presale, investors are urged to act fast and seize the opportunity to purchase $XDX tokens before they hit mainstream exchanges. Major platforms like Binance, Gate.io,...

Continue Reading
Mowi Achieves Record Volumes and Strong Financial Performance

Updated Category News Views 210

Mowi's Exceptional Performance in the Seafood Market Mowi has recently revealed outstanding financial results, showcasing revenues of €1.39 billion and an operational profit of €112 million in the latest quarter. These figures reflect a remarkable achievement despite the low salmon prices and increased supply growth in the market. Record High Salmon Volumes During a...

Continue Reading
Transformative Growth Stories in the Energy and Biotech Sectors

Updated Category News Views 164

Transformative Growth Stories in Emerging Industries The market has seen an impressive surge in small-cap energy stocks as companies across various sectors, including luxury food, next-gen biomaterials, and RNA therapeutics, announced optimistic updates. This enthusiasm is reshaping investor perceptions and laying the groundwork for robust market dynamics. Top Wealth...

Continue Reading
Cloudflare Executive Stock Sale Highlights Company Growth

Updated Category News Views 72

Cloudflare Executive Stock Sale and Company Growth Recently, Thomas J. Seifert, the Chief Financial Officer of Cloudflare, Inc. (NYSE: NET), made headlines by selling a significant amount of his stock. In this notable transaction, Seifert sold 15,000 shares of Cloudflare's Class A Common Stock for over $1.1 million. This sale was made under a pre-arranged trading plan...

Continue Reading